Novartis backs $30M round for cancer biotech; Bayer drug makes a ‘breakthrough’ at FDA
→ Ayala Therapeutics — which focuses on rare cancers that occur due to dysregulation of the Notch-activating pathway — has raised $30 million in a round of financing led by partner Novartis.
The funds, which also came from investors including SBI JI Innovation Fund, Israel Biotech Fund, aMoon and Harel Insurance & Finance Group, will be used to fuel the development of its lead drug, AL101. The pan-Notch inhibitor is currently being evaluated for adenoid cystic carcinoma (ACC) in a Phase II trial, and the company is also planning to investigate its use in a mid-stage study in triple negative breast cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.